{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:33:57Z","timestamp":1786988037036,"version":"build-2736575974"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T00:00:00Z","timestamp":1663027200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.ejca.2022.09.004","type":"journal-article","created":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T13:52:53Z","timestamp":1665150773000},"page":"121-132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study"],"prefix":"10.1016","volume":"176","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2664-902X","authenticated-orcid":false,"given":"Patricio","family":"Serra-Bellver","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3423-9912","authenticated-orcid":false,"given":"Judith M.","family":"Versluis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honey K.","family":"Oberoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6938-4685","authenticated-orcid":false,"given":"Cong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy D.","family":"Slattery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5100-0287","authenticated-orcid":false,"given":"Yasir","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0979-1625","authenticated-orcid":false,"given":"James R.","family":"Patrinely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00eas","family":"Pires da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Mart\u00ednez-Vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2606-1082","authenticated-orcid":false,"given":"Natalie","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna M.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo S.","family":"Carlino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.","family":"Menzies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana M.","family":"Arance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas B.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8894-3545","authenticated-orcid":false,"given":"Georgina V.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7579-340X","authenticated-orcid":false,"given":"Lisa","family":"Pickering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.G.","family":"Larkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian U.","family":"Blank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8875-2164","authenticated-orcid":false,"given":"Paul","family":"Lorigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15_suppl","key":"10.1016\/j.ejca.2022.09.004_bib1","doi-asserted-by":"crossref","first-page":"9506","DOI":"10.1200\/JCO.2021.39.15_suppl.9506","article-title":"CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma","volume":"39","author":"Wolchok","year":"2021","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2022.09.004_bib2","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol"},{"issue":"16","key":"10.1016\/j.ejca.2022.09.004_bib3","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ejca.2022.09.004_bib4","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined nivolumab and ipilimumab in melanoma metastatic to the brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ejca.2022.09.004_bib5","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","article-title":"Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study","volume":"19","author":"Long","year":"2018","journal-title":"Lancet Oncol"},{"issue":"15_suppl","key":"10.1016\/j.ejca.2022.09.004_bib6","doi-asserted-by":"crossref","first-page":"9508","DOI":"10.1200\/JCO.2021.39.15_suppl.9508","article-title":"Five-year overall survival from the anti-PD1 brain collaboration (ABC Study): randomized phase 2 study of nivolumab (nivo) or nivo+ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets)","volume":"39","author":"Long","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2022.09.004_bib7","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/ijc.33266","article-title":"Metastatic melanoma patient outcomes since introduction of immune checkpoint inhibitors in England between 2014 and 2018","volume":"148","author":"Board","year":"2021","journal-title":"Int J Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2022.09.004_bib8","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1245\/s10434-018-6513-7","article-title":"Melanoma staging: American Joint committee on cancer (AJCC) 8th edition and beyond","volume":"25","author":"Gershenwald","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2022.09.004_bib9","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2022.09.004_bib10","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1093\/biomet\/74.2.289","article-title":"A simple test of the proportional hazards assumption","volume":"74","author":"Gill","year":"1987","journal-title":"Biometrika"},{"issue":"1","key":"10.1016\/j.ejca.2022.09.004_bib11","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/biomet\/77.1.147","article-title":"Martingale-based residuals for survival models","volume":"77","author":"Therneau","year":"1990","journal-title":"Biometrika"},{"issue":"5","key":"10.1016\/j.ejca.2022.09.004_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001216","article-title":"Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration","volume":"9","author":"Altman","year":"2012","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.ejca.2022.09.004_bib13","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/ajco.13100","article-title":"Real-world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma","volume":"15","author":"Parakh","year":"2019","journal-title":"Asia Pac J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2022.09.004_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers12082329","article-title":"Real world outcomes of ipilimumab and nivolumab in patients with metastatic melanoma","volume":"12","author":"Asher","year":"2020","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.ejca.2022.09.004_bib15","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/pcmr.12831","article-title":"Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma","volume":"33","author":"Mason","year":"2020","journal-title":"Pigment Cell Melanoma Res"},{"issue":"14","key":"10.1016\/j.ejca.2022.09.004_bib16","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.09.004_bib17","doi-asserted-by":"crossref","first-page":"v534","DOI":"10.1093\/annonc\/mdz255.001","article-title":"Long-term outcomes from the randomized phase II study of nivolumab (nivo) or nivo+ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets): anti-PD1 brain collaboration (ABC)","volume":"30","author":"Long","year":"2019","journal-title":"Ann Oncol"},{"issue":"36_suppl","key":"10.1016\/j.ejca.2022.09.004_bib18","doi-asserted-by":"crossref","first-page":"356154","DOI":"10.1200\/JCO.2021.39.36_suppl.356154","article-title":"DREAMseq (doublet, randomized evaluation in advanced melanoma sequencing): a phase III trial\u2014ECOG-ACRIN EA6134","volume":"39","author":"Atkins","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2022.09.004_bib19","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1200\/JCO.2016.67.9258","article-title":"Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis","volume":"35","author":"D'Angelo","year":"2017","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2022.09.004_bib20","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1200\/JCO.20.00550","article-title":"Nivolumab plus ipilimumab for treatment-na\u00efve metastatic uveal melanoma: an open-label, multicenter, phase II trial by the Spanish multidisciplinary melanoma group (GEM-1402)","volume":"39","author":"Piulats","year":"2021","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2022.09.004_bib21","first-page":"449","article-title":"Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma","volume":"63","author":"Kelderman","year":"2014","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"10.1016\/j.ejca.2022.09.004_bib22","doi-asserted-by":"crossref","first-page":"e210980","DOI":"10.1001\/jamanetworkopen.2021.0980","article-title":"Validation of the American\u00a0Joint committee on cancer eighth edition staging of patients with metastatic cutaneous melanoma treated with immune checkpoint inhibitors","volume":"4","author":"Waninger","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"11","key":"10.1016\/j.ejca.2022.09.004_bib23","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1093\/neuonc\/noab094","article-title":"Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)","volume":"23","author":"Tawbi","year":"2021","journal-title":"Neuro Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2022.09.004_bib24","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1093\/neuonc\/noab046","article-title":"The combined use of steroids and immune checkpoint inhibitors in brain metastasis patients: a systematic review and meta-analysis","volume":"23","author":"Jessurun","year":"2021","journal-title":"Neuro Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922005299?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922005299?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:38:14Z","timestamp":1760733494000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922005299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":24,"alternative-id":["S0959804922005299"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.09.004","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}